Trofosfamide in non-Hodgkin's lymphoma. A phase II study.

Abstract

Twenty-three patients (12 females, 11 males) with malignant non-Hodgkin's lymphoma were treated with oral trofosfamide 50 mg t.i.d. Median age was 72 years. Fifteen patients had low-grade and 8 had high-grade lymphomas. Twenty-one patients had stage III and IV disease. Seven patients had WHO performance status of 3-4. The overall response rate was 61% (CR 22%, PR 39%) and the median duration of response 4 months (range 1.5-15+). The main side-effect was bone marrow depression and 7 patients experienced grade II or III hematological toxicity. No gastrointestinal or renal toxicity, no hair loss and no neurotoxicity were observed. The subjective tolerance was good.

• Authors: E Wist, T Risberg
• Journal: Acta oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 30 Issue 7 Pg. 819-21 ( 1991) ISSN: 0284-186X [Print] England
• PMID: 1764273 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents
• Cyclophosphamide
• trofosfamide

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (adverse effects, therapeutic use)
• Cyclophosphamide (adverse effects, analogs & derivatives, therapeutic use)
• Drug Evaluation
• Female
• Hodgkin Disease (drug therapy)
• Humans
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Middle Aged